ELCC 2020: Abstracts

Abstract submission is closed

Abstract submission deadlines

Abstract submission categories

• Tumour biology and pathology
• Translational research
• Prevention, early detection, epidemiology, tobacco control
• Imaging and staging
• SCLC
• Early stage NSCLC
• Locally advanced NSCLC
• Advanced NSCLC
• Metastases to and from the lung
• Mesothelioma
• Miscellaneous

Late-breaking abstracts (LBA)

Late-breaking abstracts may be submitted for high quality, new research findings with implications for clinical practice or understanding of disease processes.

The work must not have been previously published in any publication in a peer review setting or presented at a meeting of any other scientific organisation prior to ELCC 2020.

A preliminary abstract indicating the type of data that will be available by the late-breaking abstract deadline must be submitted online by 14 January 2020 and the intent to submit a late-breaking abstract check-box must be ticked.

Only abstracts for which no conclusive data are available at the time of the abstract submission deadline of 14 January 2020 will be considered for late-breaking status.

The final late-breaking abstract deadline of 10 March 2020 is under no circumstances to be considered as an extension of the general submission deadline.

Trial in progress abstracts (TiP)

Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to the ELCC 2020.

It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis and consequently will only require the completion of two (2) sections:

• Background
• Trial design

Notes:

• Recruitment must have already begun or have been completed by the abstract submission deadline of 14 January 2020.
• Abstracts including results or preliminary data will be rejected.
• Trial in Progress abstracts will be accepted for Poster outcome only.

Abstracts will be reviewed by the ELCC 2020 Scientific Committee and considered on the merits of the scientific and clinical rationale of the trial.

Publication schedule for accepted abstracts

1. Abstracts accepted for presentation at ELCC 2020 as Proffered Paper, Mini Oral and Poster will be published online on the ESMO website at 12:00 CEST on Wednesday, 8 April 2020.
2. Late-breaking abstracts will be made public at the start of the official Congress session during which they are presented.
3. The publication schedule of abstracts and Late-breaking abstracts selected for inclusion in the ELCC 2020 Press programme will be available 10 days before the Congress.

Presentation options for accepted abstracts

Presenters may request an outcome based on the following options. The ELCC 2020 Scientific Committee reserves the right to decide which of these session formats will be scheduled during the Congress.

Proffered Paper – Oral presentation by authors presenting original data of superior quality, followed by expert discussion and perspectives.

Mini Oral – Short presentation by authors with comment and interactive audience discussion led by invited experts.

Poster – Display session for review, discussion and questions. Presenting authors must be available for Q&A for 45 minutes to represent their work.

All accepted abstracts will be published in the ELCC 2020 Abstract Book, a supplement to the official IASLC journal, Journal of Thoracic Oncology.

Merit Awards

A restricted number of Merit Awards are reserved for candidates under 40 years of age. Selection of Merit Award recipients is based on the quality of accepted abstracts as reviewed by the Congress Scientific Committee.

More information can be found in the Abstract regulations